Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Yearbook of Oncology ◽

10.1016/j.yonc.2012.05.005 ◽

2012 ◽

Vol 2012 ◽

pp. 136-138 ◽

Cited By ~ 1

Author(s):

E.G. Chiorean

Keyword(s):

Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(11)61873-4 ◽

2012 ◽

Vol 379 (9813) ◽

pp. 315-321 ◽

Cited By ~ 784

Author(s):

Yung-Jue Bang ◽

Young-Woo Kim ◽

Han-Kwang Yang ◽

Hyun Cheol Chung ◽

Young-Kyu Park ◽

...

Keyword(s):

Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00297-7 ◽

2021 ◽

Author(s):

Xiaotian Zhang ◽

Han Liang ◽

Ziyu Li ◽

Yingwei Xue ◽

Yanong Wang ◽

...

Keyword(s):

Controlled Trial ◽

Locally Advanced ◽

Open Label ◽

Phase 3 ◽

D2 Gastrectomy ◽

Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30090-6 ◽

2018 ◽

Vol 3 (7) ◽

pp. 460-468 ◽

Cited By ~ 33

Author(s):

Yukinori Kurokawa ◽

Yuichiro Doki ◽

Junki Mizusawa ◽

Masanori Terashima ◽

Hitoshi Katai ◽

...

Keyword(s):

Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Resectable Gastric Cancer ◽

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30083-4 ◽

2019 ◽

Vol 4 (7) ◽

pp. 501-510 ◽

Cited By ~ 21

Author(s):

Yasuhide Yamada ◽

Narikazu Boku ◽

Junki Mizusawa ◽

Satoru Iwasa ◽

Shigenori Kadowaki ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00027-9 ◽

2021 ◽

Author(s):

Angela Lamarca ◽

Daniel H Palmer ◽

Harpreet Singh Wasan ◽

Paul J Ross ◽

Yuk Ting Ma ◽

...

Keyword(s):

Biliary Tract Cancer ◽

Controlled Trial ◽

Symptom Control ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Tract Cancer ◽

Folfox Chemotherapy ◽

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30088-8 ◽

2017 ◽

Vol 18 (3) ◽

pp. 371-383 ◽

Cited By ~ 21

Author(s):

Pin Zhang ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Controlled Trial ◽

Metastatic Breast ◽

Open Label ◽

Phase 3 ◽

Heavily Pretreated ◽

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61157-0 ◽

2009 ◽

Vol 374 (9698) ◽

pp. 1331-1338 ◽

Cited By ~ 494

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Fumiaki Takahashi ◽

Seiji Isonishi ◽

Toshiko Jobo ◽

...

Keyword(s):

Ovarian Cancer ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽